Khalid Malik, MD
Pulmonary Disease · Pittsburgh, PANPI 1336100296
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $144,000 of the $144,219 with a category attached, or 99.8%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 99.8% of it on its own, with 7 other manufacturers making up the rest. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $13,111 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$144K
- Novo Nordisk$73
- Chiesi USA, Inc.$52
- Vapotherm Inc$33
- Johnson & Johnson$20
- Sanofi$16
- plus $27 from 2 others
What the payments were for
- Consulting fees$144,000100%
- Food & beverage$2190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $144,000 |
| Novo Nordisk | 1 | $73 |
| Chiesi USA, Inc. | 1 | $52 |
| Vapotherm Inc | 2 | $33 |
| Johnson & Johnson | 1 | $20 |
| Sanofi | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$144,000
How this compares
$144,219 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 14 | $77,899 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $20,600 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $11,806 |
| HorizantGabapentin Enacarbil | 12 | $6,004 |
| Atrovent HfaIpratropium Bromide | 11 | $4,866 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,788 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $1,074 |
| Montelukast Sodium | 29 | $191 |
| Gabapentin | 15 | $185 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 12 | $114 |
| Pantoprazole Sodium | 17 | $38 |
| Prednisone | 20 | $15 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Pittsburgh
- Tariq CheemaPittsburgh$549K
- Stephen BashedaPittsburgh$455K
- Patrick StrolloPittsburgh$124K
- Frank SciurbaPittsburgh$119K
- Sohini GhoshPittsburgh$112K
- Brian CarlinPittsburgh$102K
- Lewis KlinePittsburgh$99K
- Sally WenzelPittsburgh$70K
- Michael ApostolisPittsburgh$61K
- Sandeep Bansaldu Bois$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.